1. Home
  2. Analysis
  3. Vimizim
  4. Methylprednisolone

Vimizim and Methylprednisolone drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Vimizim (elosulfase alfa) and Methylprednisolone (methylprednisolone). Common drug interactions include breath sounds among males.

The phase IV clinical study analyzes what interactions people have when they take Vimizim and Methylprednisolone. It is created by eHealthMe based on reports of 23 people who take the same drugs from the FDA, and is updated regularly.

What is Vimizim?

Vimizim has active ingredients of elosulfase alfa. eHealthMe is studying from 4,772 Vimizim users. Check the latest studies of Vimizim.

What is Methylprednisolone?

Methylprednisolone has active ingredients of methylprednisolone. It is often used in inflammation. eHealthMe is studying from 59,645 Methylprednisolone users. Check the latest studies of Methylprednisolone.

On Jul, 26, 2026

23 people who take Vimizim and Methylprednisolone together, and have interactions are studied.

Vimizim and Methylprednisolone drug interactions.

What are the common drug interactions of Vimizim and Methylprednisolone, by gender? *:

female:

n/a

male:

  1. Breath sounds
  2. Cough
  3. Knee deformity (functional disability of knee)
  4. Mitral valve incompetence (inefficient heart valve)
  5. Myelopathy (any neurologic deficit related to the spinal cord)
  6. Neurological decompensation (inability of brain to maintain proper function)
  7. Spinal stenosis (narrowing of spinal column)
  8. Dyspnoea (difficult or laboured respiration)
  9. Aortic valve incompetence
  10. Arthropathy

What are the common drug interactions of Vimizim and Methylprednisolone, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Atlantoaxial instability (instability of the union between the first and second cervical vertebrae)
  2. Intervertebral disc space narrowing (spinal disc space narrowing)
  3. Myelopathy (any neurologic deficit related to the spinal cord)
  4. Spinal stenosis (narrowing of spinal column)

20-29:

n/a

30-39:

n/a

40-49:

  1. Breath sounds
  2. Cough
  3. Dyspnoea (difficult or laboured respiration)
  4. Headache (pain in head)

50-59:

n/a

60+:

n/a

* Approximation only. Some reports may have incomplete information.

Do you take Vimizim and Methylprednisolone?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Vimizim and Methylprednisolone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Vimizim:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Methylprednisolone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Vimizim and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Methylprednisolone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on elosulfase alfa and methylprednisolone (the active ingredients of Vimizim and Methylprednisolone, respectively), and Vimizim and Methylprednisolone (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.